Clene Inc. 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2021. Financial statements are unaudited. Clene is a clinical-stage pharmaceutical company developing nanocrystal drug candidates; it had no approved drugs or drug-sale revenue. Reported comparative periods are Clene Nanomedicine’s historical results, presented following the December 2020 reverse recapitalization.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0.11 million | $0.10 million | $0.52 million | $0.18 million |
| Operating loss | $10.45 million | $5.69 million | $35.92 million | $14.25 million |
| Net income (loss) | $28.94 million | $(10.30) million | $(14.16) million | $(20.06) million |
| Operating cash used | Not provided for quarter | Not provided for quarter | $25.02 million | $13.12 million |
- Revenue was entirely from dietary supplements and related-party royalties, principally under an agreement with 4Life Research. No revenue came from drug candidates. Nine-month revenue rose year over year, but remained immaterial relative to expenses.
- For the nine months, cost of revenue was $0.81 million, exceeding revenue and producing a gross loss of approximately $0.29 million. The filing does not present a company-wide operating margin; operating losses were substantial.
- Q3 net income was not driven by operating performance: it included $38.48 million of non-cash gains from remeasurement of contingent earn-out liabilities, largely reflecting a decline in the share price. The company still recorded a $10.45 million operating loss for the quarter.
- Research and development expense rose to $18.89 million for nine months from $10.75 million, mainly due to clinical-trial progression, enrollment in REPAIR-PD and REPAIR-MS, and participation in the Healey ALS Platform Trial. General and administrative expense increased to $16.74 million from $3.62 million, including increased public-company costs and stock-based compensation.
- At September 30, cash was $60.55 million and restricted cash was $0.06 million; current assets were $65.39 million and current liabilities $4.83 million. Total assets were $73.04 million, total liabilities $67.35 million, and stockholders’ equity $5.69 million. Accumulated deficit was $167.72 million.
- Debt included $14.61 million of notes payable and $4.56 million of convertible notes payable, net of discounts and issuance costs. The $20 million Avenue facility carries a variable rate and is secured by substantially all assets except intellectual property. Lease obligations were $4.33 million in total. The company reported no covenant violations.
- Financing provided $27.13 million of cash during the first nine months, including $9.25 million from the May 2021 private placement and $20 million from Avenue borrowings, partially offset by costs and payments. Cash increased by $1.34 million overall. No material capital expenditure commitments were reported.
Changes, outlook, and risks
- Compared with 2020, nine-month operating loss widened by $21.67 million as R&D and G&A spending increased. Net loss narrowed, primarily reflecting earn-out fair-value gains and the prior-year preferred-stock warrant remeasurement expense, rather than improved operating profitability.
- Management said September 30 cash was expected to fund operations for more than twelve months from the financial-statement issuance date. It also expects continuing losses and higher spending as clinical programs advance, and says additional capital will be needed to fully implement its business plan. If funding or revenue is insufficient, programs or commercialization plans may be delayed, reduced, or eliminated.
- Avenue made an additional $10 million tranche available subject to conditions, including clinical-performance and equity-financing requirements. The company stated that the clinical milestone and first interest-only extension had been achieved; the additional tranche remained conditional. The loan’s stated maturity is December 2024, with a final payment of 4.25% of funded loans.
- No specific financial guidance or revenue forecast was provided. Management noted that COVID-19 had temporarily paused certain trials and created potential risks to trial execution, supply chains, and financing, although it had not caused material business disruption or asset impairment through the reporting date.
- Key risks include clinical and regulatory failure or delay, manufacturing scale-up and facility compliance, dependence on third parties and limited suppliers, future financing needs, potential dilution, and uncertainty around market adoption and reimbursement. The filing also reports that disclosure controls were ineffective due to material weaknesses in accounting resources and processes, segregation of duties, complex-transaction controls, and IT general controls. Remediation was ongoing; management did not state that the weaknesses were fully resolved.
- No material pending legal proceedings were reported. No contingent earn-out milestone had been achieved as of September 30, 2021; one clinical milestone related to a COVID-19 study had a December 30, 2021 deadline.
Investor verification priorities
- Confirm the source and non-cash nature of Q3’s $28.94 million net income, especially the $38.48 million contingent earn-out remeasurement gains.
- Track operating cash burn against the stated runway and assess the timing and conditions for any further financing.
- Review clinical-trial progress, enrollment, results, and the status of the COVID-19 earn-out milestone; no milestone had been achieved by quarter-end.
- Monitor Avenue loan covenants, variable interest costs, collateral terms, and the conditions for drawing the remaining tranche.
- Assess related-party dependence in supplement sales and royalties, alongside the absence of drug-product revenue.
- Check whether management remediates the disclosed material weaknesses and improves disclosure controls and financial reporting procedures.